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Edited by Henrik DohlmanG-protein-coupled receptors (GPCRs) are traditionally
known for signaling at the plasma membrane, but they can also
signal from endosomes after internalization to control impor-
tant pathophysiological processes. In spinal neurons, sustained
endosomal signaling of the neurokinin 1 receptor (NK1R) me-
diates nociception, as demonstrated in models of acute and
neuropathic pain. An NK1R antagonist, Spantide I (Span),
conjugated to cholestanol (Span-Chol), accumulates in endo-
somes, inhibits endosomal NK1R signaling, and causes pro-
longed antinociception. However, the extent to which the
Chol-anchor influences long-term location and activity is
poorly understood. Herein, we used fluorescent correlation
spectroscopy and targeted biosensors to characterize Span-
Chol over time. The Chol-anchor increased local concentra-
tion of probe at the plasma membrane. Over time we observed
an increase in NK1R-binding affinity and more potent inhibi-
tion of NK1R-mediated calcium signaling. Span-Chol, but not
Span, caused a persistent decrease in NK1R recruitment of β-
arrestin and receptor internalization to early endosomes. Using
targeted biosensors, we mapped the relative inhibition of NK1R
signaling as the receptor moved into the cell. Span selectively
inhibited cell surface signaling, whereas Span-Chol partitioned
into endosomal membranes and blocked endosomal signaling.
In a preclinical model of pain, Span-Chol caused prolonged
antinociception (>9 h), which is attributable to a three-
pronged mechanism of action: increased local concentration
at membranes, a prolonged decrease in NK1R endocytosis, andThis article contains supporting information.
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BY license (http://creativecommons.org/licenses/by/4.0/).persistent inhibition of signaling from endosomes. Identifying
the mechanisms that contribute to the increased preclinical
efficacy of lipid-anchored NK1R antagonists is an important
step toward understanding how we can effectively target
intracellular GPCRs in disease
G-protein-coupled receptors (GPCRs) are tractable thera-
peutic targets because they have druggable sites on the cell
surface and control most pathophysiological processes (1).
However, many GPCRs can also signal from intracellular
compartments, including endosomes, the Golgi, mitochondria,
and the nucleus (2–5). These intracellular signals dictate
physiological responses that are distinct from those that
emanate from signaling at the plasma membrane (5–10). Drug
discovery efforts typically target GPCRs at the cell surface, and
as a consequence, many drugs targeting GPCRs are not
designed to cross the plasma membrane. This inability to
effectively engage intracellular GPCRs might explain why
some drugs with high efficacy in cell-based assays of plasma
membrane signaling fail in clinical trials.
For the GPCR for substance P (SP), the neurokinin 1 re-
ceptor (NK1R), multiple NK1R antagonists have failed in
clinical trials of chronic neurological diseases, including pain
(11–13). Activation of the NK1R causes two spatially and
temporally distinct rounds of signaling (Fig. S1). At the cell
surface, SP-bound NK1R rapidly activates Gαq G proteins to
increase Ca2+ mobilization, protein kinase C (PKC) activity,
and cyclic adenosine monophosphate (cAMP) formation in the
vicinity of the plasma membrane (5, 14). Stimulation of the
NK1R also leads to transactivation of the epidermal growth
factor receptor (EGFR) to increase extracellular signal-
regulated kinase (ERK) activity in the cytoplasm. These sig-
nals are all relatively short-lived (<15 min) (14). During thisJ. Biol. Chem. (2021) 296 100345 1
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Lipid conjugation for targeting endosomal GPCRstime, GPCR kinases rapidly phosphorylate the NK1R leading to
association with β-arrestins and receptor endocytosis to early
endosomes (<2 min) (5). Within endosomes, the SP-NK1R
complex continues to signal causing increased PKC activity
and cAMP in the cytosol and increased ERK activity within the
nucleus (5, 14). These signals from the endosomally localized
receptor are longer-lived (>20 min). It is these sustained sig-
nals from the intracellular NK1R that mediate persistent
excitation of spinal neurons and sustained central pain trans-
mission (7, 14, 15).
Ligands can have spatially specific or “location biased”
pharmacological actions in cells (16). We have previously
assessed the potential for drug delivery strategies to locally
deliver NK1R antagonists to endosomes. This includes pH-
responsive nanoparticles that deliver and release the NK1R
antagonist aprepitant directly into the endosomes (17) and
lipid-anchored NK1R antagonists that accumulate in endo-
somal membranes (5). Both of these approaches improved
drug efficacy in preclinical models of pain (2–5-fold more
effective antinociception, 2–4-fold longer duration of action
compared with free drug) (5, 17). The localized delivery of an
NK1R antagonist to endosomes using nanoparticles is a se-
lective approach that bypasses any effects on receptors at the
cell surface. In contrast, lipid-anchored NK1R antagonists first
partition into the plasma membrane, before they are trafficked
to endosomes (5). It is therefore possible that lipid-anchored
antagonists also affect the signaling and trafficking of plasma
membrane-localized NK1R, in addition to their later antago-
nism of endosomal receptors. This dual antagonism—initial
blockade of plasma membrane receptors during partitioning
into the plasma membrane and then prolonged blockade of the
pathophysiologically relevant signal from endosomes—could
enhance therapeutic efficacy.
In the current investigation, we used live cell imaging and
biophysical approaches to assess NK1R signaling and traf-
ficking in subcellular compartments, in conjunction with
behavioral assays of nociception to investigate the mechanisms
by which a cholestanol-anchored antagonist, Spantide I (Span-
Chol), inhibits endosomal signaling. We used a cholestanol-
anchored fluorescent probe (Cy5-Chol) to model the lipid-
dependent translocation of the antagonist. We observed that
the lipid anchor allows an initial enrichment of probe con-
centration at the plasma membrane, which correlates with an
increased antagonist potency at proximal signaling pathways
(i.e., Ca2+ mobilization). The lipid-anchored antagonist also
inhibits cell surface NK1R-β-arrestin recruitment and NK1R
endocytosis. Over time, Cy5-Chol travels from the plasma
membrane to early and late endosomes. This movement
deeper into the endosomal network correlates with inhibition
of endosomal-selective NK1R signaling pathways (5) by Span-
Chol, including sustained cytosolic cAMP and cytosolic PKC
activity. Consistent with these findings, the lipid-anchored
antagonist has long-lasting antinociceptive actions in preclin-
ical models of pain (>9 h).
We find that lipid anchors increase the local membrane
concentration of GPCR antagonists, cause inhibition of re-
ceptor trafficking from the plasma membrane, and prolong the2 J. Biol. Chem. (2021) 296 100345inhibition of signaling from endosomes. This three-pronged
mechanism allows lipid-anchored antagonists to very effec-
tively target endosomally derived GPCR signaling pathways of
pathophysiological importance.
Results
Lipid anchors increase the available concentration of drug at
the cell surface
Inspired by prior studies using lipid–drug conjugates
(18, 19), we previously synthesized a series of lipid-anchored
probes comprising the sterol cholestanol as a lipid conjugate
for anchoring a cargo to membranes via a flexible polyethylene
glycol linker (PEG4-PEG3-PEG4) (5). For the cargo we used
Cyanine 5 (Cy5), to generate a fluorescent reporter of lipid-
anchor location (Cy5-Chol), or the NK1R antagonist, Span-
tide I, to generate a lipid-anchored antagonist (Span-Chol)
(Fig. S2). We also generated control probes including a non-
lipidated fluorescent probe (ethyl-ester group, PEG linker, Cy5;
Cy5-OEt) and a lipid anchor control probe (cholestanol group,
PEG linker, biotin; Chol).
Fluorescence correlation spectroscopy (FCS) enables mea-
surement of the concentrations offluorescentmoleculeswithin a
small defined volume (<0.2 fl) (20, 21).We used this approach to
determine the concentration of Cy5 probes (Cy5-Chol or the
control, Cy5-OEt) in the extracellular fluid immediately above
the plasma membrane and at increasing distances above the cell
(30–200 μm). We chose the Cy5 probes as the simplest example
of how a lipid anchor could affect the plasma membrane con-
centration of a cargo, independent of any receptor-dependent
effects on ligand distribution (22). Consistent with our previ-
ous studies (5), brightfield and fluorescence confocal imaging
confirmed that Cy5-Chol rapidly incorporated into the plasma
membrane of HEK293 cells (Fig. 1A), but Cy5-OEt remained in
extracellular fluid (Fig. 1B). We then used FCS to quantify the
concentration of Cy5 fluorescence at the plasma membrane of
cells incubated with a nominal concentration of probe (10 nM).
The concentration of Cy5-Chol in the extracellular fluid at 5 μm
above the plasmamembranewas 23.8 ± 7.1 nM,which decreased
more than fourfold to 5.6 ± 1.4 nM at 30 μm (mean ± SEM from
n = 4) (Fig. 1, C and E). In contrast, the measured concentration
of Cy5-OEt was 6.5 ± 1.1 nM at 5 μm above the plasma mem-
brane, which increased more than threefold to 21.8 ± 3.8 nM at
200μm(mean± SEM fromn= 4) (Fig. 1,D andE). A comparison
of probe concentrations at increasing distances (5 μm intervals)
above the plasma membrane suggested that there was an
enrichment of Cy5-Chol proximal to the plasma membrane,
while the Cy5-OEt reporter molecule could freely diffuse
through the extracellular fluid (Fig. 1E). Therefore, the addition
of a lipid anchor results in an enhanced association of a probe
with cell membranes. This creates a high local concentration of
probe at the cell surface.
Lipid anchoring increases the affinity and potency of an NK1R
antagonist
To determine whether the addition of a lipid anchor in-
fluences the affinity and potency of an NK1R antagonist, we
Figure 1. A cholestanol lipid anchor increases the concentration of Cy5 immediately above the plasma membrane. A and B, Confocal images of
HEK293 cells after incubation with 1 μM Cy5-Chol (A) or Cy5-OEt (B). Arrows indicate intracellular Cy5 fluorescence, and arrow heads indicate Cy5 fluo-
rescence at the plasma membrane. Scale bar, 20 μm. C and D, the concentration of 10 nM solution of Cy5-Chol (C) or Cy5-OEt (D) at increasing distances
above the plasma membrane of HEK293 cells was calculated using FCS. Data points show the concentrations measured at six distance intervals averaged
from 3 to 4 independent experiments. The nominal concentration of the added solution (10 nM) is shown by a dashed line. E, the concentration of Cy5-Chol
and Cy5-OEt binned at increasing 5 μm intervals above the plasma membrane. Bars show the mean, error bars show the standard error of the mean (S.E.M.),
and data points show the average concentrations obtained from each individual experiment (n = 4). *p < 0.05, **p < 0.01 Cy5-OEt vs Cy5-Chol; two-way
ANOVA with Sidak’s multiple comparison test.
Lipid conjugation for targeting endosomal GPCRscompared unconjugated (“free”) Spantide I (Span) and Span-
Chol. A high-content imaging competition binding assay
was used to evaluate the capacity of these antagonists to
disrupt the binding of SP labeled with fluorescent tetrame-
thylrhodamine (SP-TAMRA) to the NK1R stably transfectedin HEK293 cells. Cells were analyzed using an established
granularity algorithm to provide a measure of total cell
binding (includes both cell surface and intracellular)
(21, 23). We assessed antagonist affinity at two time points
following antagonist addition: 30 min, when FCS data showJ. Biol. Chem. (2021) 296 100345 3
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4 h, when Span-Chol accumulates, and is pharmacologically
active, within endosomal compartments (5).
To assess competition binding after 30 min, HEK-
NK1R cells were coincubated with an EC50 concentration of
SP-TAMRA (0.5 nM) and increasing concentrations of Span
or Span-Chol and equilibrated for 30 min. The affinity of
Span-Chol and Span for NK1R was similar with pIC50 values of
6.28 ± 0.09 and 5.99 ± 0.13, respectively (Fig. 2A). Therefore,
peptide modification by attachment of a PEG12 linker and
cholestanol anchor does not diminish the affinity of Spantide
for the NK1R.
To assess ligand binding after 4 h, HEK-NK1R cells were
preincubated with antagonist for 3.5 h, then with SP-TAMRA
for a further 30 min (4 h total). The affinity of Span for the
NK1R was significantly reduced compared with that of Span-
Chol (pIC50 5.55 ± 0.17 vs 6.50 ± 0.12, p = 0.0018, unpaired
t-test) (Fig. 2B). However, there was no significant change in
the relative affinities of Span or Span-Chol for the NK1R over
time (p = 0.1121 and p = 0.6378, respectively; one-way ANOVA
with Tukey’s multiple comparisons test). This suggests that the
addition of a lipid anchor improves the kinetic properties of
Span by sustaining its ability to compete with SP-TAMRA at
the NK1R over a 4 h period. Our previous studies indicated no
difference in stability of these ligands in spinal cord membranes
(5). We therefore propose that this apparent improvement in
affinity of Span-Chol for the NK1R is due to the accumulation
of Span-Chol in endosomes, allowing Span-Chol to access both
plasma membrane and endosomal pools of NK1R.Figure 2. A cholestanol lipid anchor increases the relative affinity and pote
Chol was assessed by competition with fluorescent SP-TAMRA in HEK-NK1R ce
vehicle (0.1% v/v DMSO; total binding) or increasing concentrations of Span o
0.5 nM SP-TAMRA. Data are expressed as a percentage of the fluorescent inte
Symbols show means, and error bars S.E.M. of five independent experiments
NK1R cells in response to 1 nM SP following short (30 min; C) or long (4 h; D)
Four-h preincubation experiments compared continuous exposure to antagon
Symbols show means, and error bars S.E.M. of three independent experiment
4 J. Biol. Chem. (2021) 296 100345To determine if lipid conjugation influenced the potency of
Span, we compared the ability of Span and Span-Chol to
inhibit SP-stimulated Ca2+ signaling in HEK-NK1R cells at
different time points after addition. In initial experiments,
HEK-NK1R cells were preincubated with increasing concen-
trations of Span or Span-Chol for 30 min, prior to challenge
with an EC80 concentration of SP (1 nM). Ca
2+ transients were
measured for 90 s poststimulation. Preincubation of cells with
Span or Span-Chol caused a concentration-dependent inhibi-
tion of Ca2+ flux (Fig. 2C). A comparison of the pIC50 values of
Span and Span-Chol (4.87 ± 0.33 and 6.25 ± 0.19, respectively)
revealed a significant increase in the potency of the lipidated
antagonist (p = 0.0112). This is consistent with FCS experi-
ments (Fig. 1) and may be due to the lipid anchoring of the
antagonist to the plasma membrane, thereby effectively
increasing the local concentration of the antagonist near the
receptor even at acute time periods (24, 25).
While lipid-anchored fluorescent probes initially partition
into the plasma membrane, they are then quickly trafficked
into endosomal compartments (5). As such, the continuous
removal of lipidated antagonists from the plasma membrane
by constitutive endocytosis could affect the relative potency of
Span-Chol compared with soluble Span over time. To assess
this possibility, we compared continuous exposure to the an-
tagonists for 4 h to a “pulsed” administration whereby the cells
were preincubated with antagonist for 30 min, washed to
remove any excess ligand, and then left at 37C for 3.5 h (4 h
total). In both protocols, cells were challenged with 1 nM SP
4 h after the initial antagonist addition. There was no changency of an NK1R antagonist. A and B, the affinity of Span compared to Span-
lls by high-content imaging (n = 5). HEK-NK1R cells were preincubated with
r Span-Chol for a total of 30 min (A) or 4 h (B) at 37C prior to addition of
nsity measured in the presence of 10 nM Span or Span-Chol (%FLUORMax).
performed in triplicate. C and D, Calcium transients were measured in HEK-
preincubation with increasing concentrations of Span or Span-Chol (n = 3).
ist (4 h) versus a “pulsed” exposure (0.5 h exposure, wash [W], 3.5 h rest).
s performed in triplicate.
Lipid conjugation for targeting endosomal GPCRsin the pIC50 of the antagonists when the cells were continu-
ously incubated with Span or Span-Chol for 4 h (5.11 ± 0.76
and 6.36 ± 0.17, respectively) compared with the 30 min
preincubation (Fig. 2D).
After pulsed administration, only Span-Chol retained its
ability to antagonize SP-stimulated Ca2+ signaling at 4 h (pIC50
6.15 ± 0.11) (Fig. 2D). This is likely due to the wash step (after
the initial 30 min incubation with antagonist) decreasing the
available concentration of free Span in the extracellular fluid.
In contrast, the potency of Span-Chol was not lost following
the wash, confirming that lipidation causes an increased as-
sociation of the antagonist with the cell membrane. Notably,
the potency of Span-Chol was sustained over 4 h despite the
increasing internalization of lipid-anchored probes over time
(5). This could indicate a prolonged retention of the lipid-
anchored antagonist at the plasma membrane (in addition to
internalization into the endosomal network).Figure 3. Span-Chol causes sustained inhibition of NK1R-induced recruitm
effect of short (30 min) versus long (pulsed 4 h: 30 min treatment, wash, 3.
recruitment of β-arrestin and receptor internalization to early endosomes was
BRET between NK1R-Rluc8 and β-arrestin 2-YFP after preincubation with 10 μM
calculated from curve fit of the BRET time courses (as per A and B) after prein
alone. D–F, 1 nM SP-induced change in BRET between NK1R-Rluc8 and KRas-V
pulsed 4 h (E). F, the plateau response calculated from curve fit of the BRET tim
antagonist, expressed relative to SP alone. G–I, 1 nM SP-induced change in B
Span or Span-Chol for 30 min (G) or pulsed 4 h (H). I, the plateau response
preincubation with 0.1 μM, 1 μM, or 10 μM antagonist, expressed relative to SP
graphs, columns show means, error bars show S.E.M., and symbols show the m
0.01 and ***p < 0.001 versus SP alone, two-way ANOVA with Dunnett’s multiTogether, these data demonstrate that cholestanol conju-
gation can enhance the potency and affinity of antagonists by
increasing their retention in the plasma membrane and
therefore their effective local concentration.
A lipid-anchored antagonist decreases endocytosis of the
activated NK1R
Span-Chol has a high local concentration at the cell surface
(Fig. 1) and maintains antagonistic activity at cell surface re-
ceptors even after 4 h (Fig. 2). It is therefore possible that
lipidated antagonists continually act at the plasma membrane
to inhibit SP-induced endocytosis of the NK1R, which could
contribute to their long-lasting therapeutic efficacy. To assess
this possibility, we measured the proximity between NK1R-
RLuc8 and β-arrestin2-YFP, KRas-Venus (marker of the
plasma membrane), or Rab5a-Venus (marker of early endo-
somes) in HEK293 cells using BRET. We compared theent of β-arrestin and receptor internalization to early endosomes. The
5 h recovery) preincubation with Span or Span-Chol on the NK1R-induced
determined using BRET in HEK cells (n = 6). A–C, 1 nM SP-induced change in
Span or Span-Chol for 30 min (A) or pulsed 4 h (B). C, the plateau response
cubation with 0.1 μM, 1 μM, or 10 μM antagonist, expressed relative to SP
enus after preincubation with 10 μM Span or Span-Chol for 30 min (D) or
e courses (as per D and E) after preincubation with 0.1 μM, 1 μM, or 10 μM
RET between NK1R-Rluc8 and Rab5a-Venus after preincubation with 10 μM
calculated from curve fit of the BRET time courses (as per G and H) after
alone. For time courses, symbols show means and error bars S.E.M; for bar
ean of each individual experiment performed in duplicate. *p < 0.05, **p <
ple comparisons test.
J. Biol. Chem. (2021) 296 100345 5
Lipid conjugation for targeting endosomal GPCRseffectiveness of Span versus Span-Chol after short (30 min) or
prolonged (4 h) incubation. In order to observe any differences
between the antagonists that were due to the prolonged
retention of Span-Chol at the cell surface, we used the “pulsed”
incubation protocol: 30 min antagonist, wash, 3.5 h recovery
(4 h total).
In control cells, SP induced an increase in NK1R-RLuc8/β-
arrestin2-YFP BRET, consistent with β-arrestin2 recruitment
to NK1R (Fig. 3, A–C). After 30 min preincubation, Span and
Span-Chol (0.1, 1, or 10 μM) caused a concentration-
dependent inhibition of SP-stimulated NK1R-RLuc8/β-
arrestin2-YFP BRET. After a pulsed 4 h preincubation with
antagonists, Span had no effect on SP-stimulated NK1R-
RLuc8/β-arrestin2-YFP BRET at any concentration (Fig. 3, B
and C). In contrast, Span-Chol inhibited SP-stimulated NK1R-
RLuc8/β-arrestin2-YFP BRET at the two highest concentra-
tions of antagonist (1 and 10 μM).
Similar results were obtained when we measured the effect
of Span or Span-Chol on the SP-stimulated change in BRET
between NK1R-RLuc8 and KRas-Venus (Fig. 3, D–F) or Rab5a-
Venus (Fig. 3, G–I). In control cells, SP caused a decrease in
BRET between NK1R-RLuc8 and KRas-Venus (Fig. 3, D–F),
which corresponded to an increase in BRET between NK1R-
RLuc8 and Rab5a-Venus (Fig. 3, G–I). This is consistent with
receptor internalization from the plasma membrane (KRas) to
early endosomes (Rab5a). After a 30 min preincubation, both
Span and Span-Chol inhibited the SP-stimulated change in
BRET between NK1R-RLuc8 and KRas-Venus (Fig. 3, D and F)
or Rab5a-Venus (Fig. 3, G and I). However, after a pulsed 4 h
preincubation, only Span-Chol inhibited the SP-stimulated
change in BRET between NK1R-RLuc8 and KRas-Venus
(Fig. 3, E and F) or Rab5a-Venus (Fig. 3, H and I).
Since alterations in the composition of membrane lipids
could artifactually affect BRET between transmembrane and
associated proteins, we also studied the effects of a control
cholestanol-PEG-biotin probe (Chol). There was no effect of
any tested concentration of Chol (0.1, 1, 10 μM) on the SP-
induced changes in BRET between NK1R-RLuc8 and β-
arrestin2-YFP, KRas-Venus, or Rab5a-Venus (Fig. S3).
Our results show that Span-Chol can antagonize the NK1R
at the plasma membrane to inhibit β-arrestin2 recruitment and
receptor endocytosis. This effect is prolonged for up to 4 h,
suggesting that some Span-Chol is retained at the plasma
membrane despite significant movement of the lipid-anchored
antagonist into endosomes (5).
Lipid-anchored probes traffic from the plasma membrane to
endosomal compartments
We have previously demonstrated that the Cy5-Chol probe
accumulates in early endosomes in HEK293 cells after 4 h, as
indicated by colocalization with Rab5a (5). However, we still
observe effects of Span-Chol at the plasma membrane at this
time point, and the distribution of lipid-anchored probes into
other endosomal signaling compartments (i.e., late endo-
somes) has not been investigated. We therefore set out to map
the location of Cy5-Chol over short and longer timescales.6 J. Biol. Chem. (2021) 296 100345Previous studies have shown accumulation of a fluorescent
analog of Span-Chol (Cy5-Span-Chol) in NK1R-positive
endosomes in cells stimulated with SP (5). Here, we aimed to
further define the role of the lipid anchor in influencing the
cellular distribution of cargo when not engaged with its re-
ceptor target (Fig. 4).
HEK293 cells were infected with CellLight fluorescent
fusion proteins resident to endocytic compartments,
including early endosomes (EE-RFP) and late endosomes (LE-
GFP). The distribution of Cy5-Chol (1.5 μM) was examined in
live cells by confocal microscopy due to a loss of probe
fluorescence that occurs when using standard fixation ap-
proaches. Using this approach, some of the finer endosomal
structures are less evident in comparison with antibody
staining of Rab GTPases in fixed cells (26). Nevertheless, live
cell imaging still provides valuable insights into the distribu-
tion of lipidated probes within the endosomal network over
time. After a 30 min preincubation, Cy5-Chol fluorescence
was readily observed at the plasma membrane, in early
endosomes (EE-RFP) and late endosomes (LE-GFP) (Fig. 4A).
A much higher proportion of Cy5-Chol was observed at the
plasma membrane, compared with intracellular compart-
ments (Fig. 4B). We then assessed distribution of Cy5-Chol
after a pulsed incubation protocol (30 min incubation with
Cy5-Chol, wash, 3.5 h recovery; 4 h total). We observed
coincident detection of Cy5-Chol with markers of early
endosomes (EE-RFP) and late endosomes (LE-GFP) (Fig. 4C).
This correlated with a change in the overall distribution of
Cy5-Chol in the cell, with similar fluorescence observed at the
plasma membrane and within intracellular compartments
(Fig. 4D). To determine the long-term intracellular distribu-
tion of a lipidated probe, HEK293 cells were incubated with
Cy5-Chol for 24 h (Fig. 4, E and F). After 24 h we still detected
Cy5-Chol codistribution with reporters for early endosomes
(EE-RFP) and late endosomes (LE-GFP) (Fig. 4E). However,
the relative distribution of Cy5-Chol over the whole cell was
enriched in intracellular compartments compared with the
plasma membrane (Fig. 4F).
Together, these data indicate that the internalized
cholestanol-conjugated reporter resides within the endocytic
pathway for sustained periods. Over time, the amount of Cy5-
Chol at the plasma membrane decreases, which corresponds
with a movement of Cy5-Chol further into the endosomal
network. These findings support the use of sterol-based lipid
anchors for targeting ligands to populations of endosomal
GPCRs.
Only free antagonist completely blocked plasma membrane
NK1R signaling
We then investigated in detail the capacity of Span versus
Span-Chol to target NK1R signaling in different cellular re-
gions. Our previous analysis had focused only on ERK activity,
showing selective inhibition of nuclear ERK by Span-Chol
(versus Span) (5). This is because only endosomal NK1R can
increase nuclear ERK in response to SP (5). Here, we used an
expanded toolbox of targeted FRET biosensors to follow the
Figure 4. The cholestanol lipid anchor causes Cy5 movement from the plasma membrane deeper into endosomal pathways over 24 h. The location
of the Cy5-Chol probe (1.5 μM) was determined after 30 min (A, B), 4 h (C, D) or 24 h (E, F) by confocal microscopy in HEK cells labeled with location markers
of the endosomal network (CellLight: early endosome(EE)-RFP or late endosome(LE)-GFP) (n=4–6). A, C, E, representative, merged and zoomed images of
HEK cells with location markers pseudocolored green, after 30 min incubation with Cy5-Chol (pseudocolored magenta). Dotted box indicates zoomed region
for inset image. Arrow heads indicate coincidence of the Cy5-Chol with the location marker. Orange line indicates region highlighted in line scan intensity
graph (right panel), with the start of the line indicated by a circle. Scale bar, 20 μm. B, D, F, the proportion of Cy5-Chol fluorescence at the plasma membrane
compared with the rest of the cell (defined as intracellular Cy5). Bars show the grouped mean, and error bars represent S.E.M. of grouped cells from 4 to 6
independent experiments. ***p < 0.001, unpaired t-test.
Lipid conjugation for targeting endosomal GPCRssignaling of the NK1R in live cells as the receptor moves from
the plasma membrane to early endosomes.
SP stimulation of NK1R at the cell surface causes activation
of Gαq signaling, which is limited to the plasma membrane
(5, 14). NK1R-Gαq stimulates phospholipase C (PLC)-depen-
dent formation of inositol trisphosphate (InsP3) and diac-
ylglycerol (DAG). InsP3 causes the transient release of Ca
2+
(Fig. 2), and then both DAG and Ca2+ activate protein kinase C
(PKC). PKC can then activate adenylyl cyclase (AC) to increase
cAMP (Fig. S1).
We can measure changes in these transient signals from the
NK1R at the plasma membrane of live cells. In HEK293 cellstransfected with HA-NK1R and a PKC FRET biosensor
(cytoCKAR), fast imaging shows a transient increase in PKC
activity in response to SP, which declined to a steady-state
level by 30 s following receptor stimulation (Fig. 5A). In
HEK293 cells transfected with HA-NK1R and a plasma
membrane cAMP FRET biosensor (pmEpac2), this transient
PKC signal was followed by a slightly delayed but also transient
increase in cAMP at the plasma membrane in response to SP.
With a peak at 5 min, the cAMP response then declined
slowly toward baseline (Fig. 5B). This high-resolution exami-
nation of localized signaling allowed us to assemble a timescale
of events at the plasma membrane following NK1R stimulationJ. Biol. Chem. (2021) 296 100345 7
Figure 5. Only Span inhibits all NK1R signaling from the plasma membrane. After a 4 h preincubation Span, but not Span-Chol, blocks SP-stimulated
transient increases in PKC activity and cAMP (n = 3). A and B, HEK cells transfected with HA-NK1R and cytoCKAR (A) or pmEpac2 (B) were stimulated with
vehicle (0.0001% v/v MilliQ H2O) or 1 nM SP and signaling was measured over time. C, Cartoon of the sequence of events following NK1R stimulation at the
plasma membrane. Orange circles indicate the time at which a regulatory event starts, and vertical orange lines indicate when it reaches a plateau. Signaling
is represented by black lines. D–G, HEK cells transfected with HA-NK1R and cytoCKAR (D–E) or pmEpac2 (F–G) were pretreated with 1 μM Span (D, F) or Span-
Chol (E, G) for 4 h prior to addition of vehicle (0.0001% v/v MilliQ H2O) or 1 nM SP. Data are expressed as the FRET relative to the baseline FRET (F/F0). Arrows
indicate time of vehicle/SP addition. Symbols show the mean, and error bars S.E.M. of grouped cells from three independent experiments.
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Figure 6. Only Span-Chol, and not Span, inhibits NK1R signaling from
endosomes. After a 4 h preincubation Span-Chol, but not Span, blocks SP-
stimulated sustained increases in PKC and cAMP (n = 3). A and B, HEK cells
transfected with HA-NK1R and cytoCKAR (A) or cytoEpac2 (B) were stimu-
lated with vehicle (0.0001% v/v MilliQ H2O) or 1 nM SP and signaling was
measured over 20 min. C, cartoon of the sequence of events in endosomes
following NK1R stimulation. β-arr, β-arrestin. The orange circle indicates the
time at which internalization starts, and the vertical orange line indicates
Lipid conjugation for targeting endosomal GPCRs(Fig. 5C). The activated receptor causes a fast peak of both
Ca2+ and PKC activity in the first 30 s, which overlaps the start
of the transient cAMP and cytosolic ERK signals. The peak of
cAMP and cytosolic ERK signaling coincides with a plateau in
the recruitment of β-arrestins (2–5 min post receptor stimu-
lation) (5). The cAMP and cytosolic ERK signals then decline
back toward baseline, which coincides with a plateau in the
internalization of NK1R to early endosomes (10–15 min post
receptor activation) (5).
Using this timescale of events at the cell surface, we assessed
the relative impact of Span versus Span-Chol on NK1R
signaling from the plasma membrane. We used a continuous
incubation protocol for 4 h, so as not to wash away the free
Span. This allows us to compare the spatial efficacy of both
antagonists. A 4 h preincubation of the cells with Span
inhibited the fast peak of PKC activity in response to SP, but
there was no effect of Span-Chol on this signal (Figs. 5, D and
E, S4, A and B). Similarly, a 4 h preincubation of the cells with
Span inhibited the SP-induced increase in cAMP at the plasma
membrane, with no effect of preincubation with Span-Chol on
this signal (Figs. 5, F and G, S4, C and D).
These data suggest that while Span-Chol effectively blocks
Ca2+ mobilization (Fig. 2), it is unable to block the PKC and
cAMP signals activated by the SP-stimulated NK1R at the
plasma membrane. In contrast, free Span inhibits all signaling
of the plasma-membrane-localized receptor (Ca2+, PKC and
cAMP).
Only a lipid-anchored antagonist can inhibit endosomal NK1R
signaling
Following NK1R activation by SP, there is a rapid recruit-
ment of β-arrestins and internalization of the receptor to early
endosomes. Here, the NK1R also colocalizes with Gαq and
causes a sustained increase in PKC, cAMP, and ERK (5)
(Fig. S1).
We can measure changes in these sustained signals from the
NK1R in endosomes of live cells. In HEK293 cells transfected
with the HA-NK1R and cytoCKAR, high content imaging over
20 min showed a steep increase in PKC activity by 1 min,
which was sustained over the measurement period (Fig. 6A).
Similarly, in HEK293 cells transfected with HA-NK1R and a
cytosolic cAMP FRET biosensor (cytoEpac2), we observed a
prolonged increase in cAMP, which peaked by 2 min and was
sustained over the 20 min period (Fig. 6B). This high-
resolution examination of localized signaling allowed us to
define a timescale of events at early endosomes following
NK1R stimulation (Fig. 6C). The activated NK1R rapidlywhen it reaches a plateau. Signaling is represented by black lines. D–H, HEK
cells transfected with HA-NK1R and cytoCKAR (D–E) or cytoEpac2 (F–G) were
pretreated with 1 μM Span (D, F) or Span-Chol (E, G) for 4 h prior to addition
of vehicle (0.0001% v/v MilliQ H2O) or 1 nM SP. Symbols show the mean,
and error bars represent S.E.M. of grouped cells from three independent
experiments. H, smoothed time course traces showing the change in
effectiveness of Span versus Span-Chol at blocking SP-stimulated PKC
signaling as the NK1R transitions from the plasma membrane (data taken
from Fig. 5A) to endosomes (data from Fig. 6A). Data are expressed as the
FRET relative to the baseline FRET (F/F0). Arrows indicate time of vehicle/SP
addition.
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Figure 7. Span-Chol causes a prolonged antinociception in mice up to 9 h post administration. The analgesic effects of Span-Chol were assessed over
16 h in a mouse model of mechanical nociception (n = 6). A, illustration of the experimental protocol: Span (50 μM), Span-Chol (50 μM), Chol (50 μM), or
vehicle (1% v/v DMSO/saline) was administered by intrathecal (i.t.) injection to three different groups of mice. The mice were left for 12 h (group 1), 6 h
(group 2), or 3 h (group 3) before intraplantar (i.pl.) injection of capsaicin (CAP, 5 μg, 10 μl). Paw withdrawal responses to stimulation with von Frey filaments
were measured hourly for 4 h. B–D, Paw withdrawal responses measured in the different groups of mice at 3 h (B), 6 h (C), or 12 h (D) after i.t. drug
administration. Data are expressed relative to the baseline paw withdrawal threshold established for each mouse at the start of the experiment. Symbols
show the mean, and error bars represent S.E.M. from 6 mice. ***p < 0.001 compared with mice that received i.t. vehicle, two-way ANOVA with Bonferroni
posttest.
Lipid conjugation for targeting endosomal GPCRstraffics to early endosomes that also contain Gαq within 1 min
post receptor stimulation (5). This movement corresponds
with a rapid and sustained increase in PKC activity and cAMP
over very similar timescales. The sustained increase in nuclear
ERK mediated by endosomal NK1R is slightly delayed and
peaks 10 min post receptor stimulation (5).
To compare the effect of Span versus Span-Chol on NK1R
signaling from early endosomes, we used a 4 h continuous
incubation protocol. Under these conditions, Span had no
effect on the SP-induced increase in PKC or cAMP (Figs. 6, D
and E, S4, E–H). In contrast, preincubation for 4 h with Span-
Chol inhibited SP-induced PKC and cAMP signaling (Figs. 6, F
and G, S4, E–H).
Given the clear time distinction between the two PKC
events stimulated by the plasma membrane versus endosomal
NK1R, we can visualize the changing spatial efficacies of the
two antagonists (Figs. 6H, S4I). Under control conditions,
spatiotemporal coordination of PKC activity is observed,
where SP causes an initial peak in PKC activity from the
plasma membrane NK1R and then a steady increase in PKC
activity from endosomal NK1R. Signaling waves of this nature
may be mediated due to spatially dependent activation of
differentially localized PKC isoforms (27, 28).10 J. Biol. Chem. (2021) 296 100345A long preincubation with Span inhibits the PKC signal
from cell surface NK1R but has no effect on the PKC signals
activated by endosomal NK1R. In contrast, long preincubation
with Span-Chol has no effect on the initial PKC signal from the
activated cell surface NK1R, but selectively inhibits signals
from the endosomal NK1R. These data suggest that free Span
effectively inhibits plasma-membrane-delimited signaling but
is unable to block signaling driven by intracellular NK1R. In
contrast, Span-Chol favors inhibition of PKC and cAMP sig-
nals activated by SP-NK1R from endosomes.
The three-pronged mechanism of action of Span-Chol
contributes to its long-lasting antinociceptive actions
We have previously demonstrated that blockade of endo-
somal (compared with plasma membrane) NK1R causes much
more effective antinociception (5, 17). In preclinical models of
pain, the analgesic effect of Span-Chol was maintained for up
to 6 h (5). However, it is unknown for how long this analgesic
effect is sustained. We recently examined the analgesic effect
of an NK1R antagonist (aprepitant) over a 24 h period after
directly delivering it to endosomes and found that anti-
nociception was maintained for 6 h, before dropping back to
baseline (17).
Lipid conjugation for targeting endosomal GPCRsThe three-pronged mechanism of Span-Chol identified in
this study (higher local concentration at membranes,
decreased receptor internalization, and complete inhibition of
endosomal signaling) suggested that Span-Chol could provide
prolonged pain relief. To evaluate this possibility, Span, Span-
Chol, or controls were administered by intrathecal injection to
three different groups of mice (Fig. 7A). Each group received
an injection of capsaicin into the plantar surface of the left
hindpaw at different times after intrathecal administration of
the antagonists (i.e., capsaicin injected 3 h, 6 h, or 12 h after
antagonist administration). Mechanical nociception was eval-
uated by measurement of paw withdrawal responses to stim-
ulation of the plantar surface with calibrated von Frey
filaments every hour for 4 h after administration of capsaicin.
As mechanical nociception to capsaicin was measured over
exactly the same time period for all groups (4 h), this allowed
us to build a timescale of the analgesic effect of Span-Chol over
a cumulative 16 h period (Fig. 7).
In control mice receiving intrathecal vehicle, capsaicin
caused a prolonged allodynia over 4 h (Fig. 7, B–D). Neither
free Span nor the Chol control had any effect at any time
tested. In contrast, Span-Chol had a marked antinociceptive
action that was already present at 4 h post intrathecal injection
and was fully maintained for 9 h after intrathecal injection.
Thus, intrathecal delivery of Span-Chol resulted in a long
duration of antinociception.Discussion
The NK1R is expressed throughout the nervous, immune,
digestive, respiratory, and urogenital systems, where it reg-
ulates pain, inflammation, motility, and secretion (29–34). In
the context of pain, noxious stimuli evoke the release of SP
from peripheral and central projections of primary afferent
neurons. In the dorsal horn of the spinal cord, SP then ac-
tivates the NK1R on second-order spinal neurons to mediate
pain transmission (29). Despite this clear role in pain
transmission, there has been limited clinical success for drug
discovery programs targeting the NK1R for chronic pain
(29, 35). Previously, we reported that pain transmission is
dependent on sustained signaling from the NK1R internal-
ized to endosomes and that we could improve analgesic ef-
fect and duration in preclinical models of pain by specifically
blocking endosomal (and not cell surface) NK1R (5, 17).
Here, in addition to blockade of endosomal NK1R, we have
identified two further effects of a lipid-anchored NK1R
antagonist that contribute to its increased efficacy. First, we
find that the addition of a lipid anchor causes a fourfold
increase in the local concentration of a probe directly above
the cell membrane. Second, although the probe quickly in-
ternalizes, 29.6% of the lipid-anchored probe remains at the
plasma membrane even 24 h after administration. This re-
sidual plasma membrane localization facilitates an inhibition
of NK1R trafficking to endosomes. Together, this three-
pronged mechanism—increased local concentration, inhibi-
tion of NK1R trafficking to endosomes, and sustained
blockade of endosomal signaling—contributes to theprolonged analgesic effects of lipidated antagonists in pre-
clinical models of pain.
Cholestanol has a high affinity for sterol-rich microdomains
of the outer leaflet of lipid bilayers. The binding of cholestanol
to the sterol-rich microdomains then promotes internalization
into endosomal compartments (36). Cholestanol has also been
used to target an inhibitor of the recycling endopeptidase, β-
site amyloid precursor protein cleaving enzyme 1 (BACE-1), to
early endosomes (37). A lipid conjugated, but not a free
antagonist, inhibited the cleavage of amyloid precursor protein
at the BACE-1 ectodomain, a rate-limiting step in the pro-
duction of the β-amyloid peptide. We subsequently used this
approach to target an NK1R antagonist to endosomes and
observed a prolonged and seemingly selective inhibition of
endosomal compared with plasma membrane NK1R signaling
(5). However, with further investigation we now find that the
effects of a cholestanol-conjugated NK1R antagonist are not
limited to blockade of endosomal signaling. In addition to
delivery to endosomes, we found that cholestanol conjugation
causes a prolonged increase in the partitioning of the cargo
into the plasma membrane. This is consistent with previous
studies using Cy5-Chol or Cy5-Span-Chol that show fluores-
cent probe distribution in both endosomes and the plasma
membrane over time (5). Increasing the lipophilic properties of
soluble drugs, such as GPCR antagonists, can increase their
association with membranes and may therefore enhance their
local potency (24, 38). Here we found that the addition of
cholestanol caused approximately fourfold increase in the
concentration of Cy5 directly above the plasma membrane
when we measured Cy5-Chol compared with Cy5-OEt con-
centrations using FCS. Although we did not directly measure
the concentration of Span-Chol itself, a previous study re-
ported a twofold local enrichment of the concentration of a
GPCR ligand at the surface of cells transfected with the target
GPCR, compared with nontransfected cells (22). This increase
in local concentration was achieved without any change in the
lipophilic properties of the ligand itself. As such, we would
expect the local concentration of a lipid-anchored GPCR
ligand to be at least fourfold higher at the surface of target
cells. Consistent with this, we observed a corresponding in-
crease in the potency and affinity of Span-Chol as compared
with Span. This suggests that the blockade of endosomal
signaling of the NK1R by Span-Chol is not only due to its
spatial distribution but could also be influenced by a high local
concentration of Span-Chol at endosomal membranes.
Given the inherent ability of cholestanol conjugation to
cause a prolonged increase in partitioning into membranes, it
is important to map where the probes travel in cells. After
initial incorporation into the plasma membrane, cholestanol
probes translocate from the plasma membrane to endosomes.
Within endosomes, cholestanol-conjugated antagonists inhibit
the endosomal signaling of the NK1R that underlies persistent
excitation of spinal neurons and pain transmission (5).
Consistent with our previous study, we find that Cy5-Chol is
rapidly internalized into the endosomal network where it is
codistributed with early and late endosomes. Despite this large
movement of the Cy5-Chol into the cell, some of the probeJ. Biol. Chem. (2021) 296 100345 11
Lipid conjugation for targeting endosomal GPCRsremains at the plasma membrane even after 24 h. This
persistent partitioning of Cy5-Chol into the plasma membrane
led us to look for an effect of Span-Chol on NK1R endocytosis.
BRET receptor trafficking studies revealed that up to 4 h after
a pulse administration of Span-Chol, the lipid-anchored
antagonist could inhibit receptor trafficking by blocking the
recruitment of β-arrestins and therefore, subsequent receptor
internalization to early endosomes. This inhibition of receptor
movement into endosomes likely contributes to the overall
decrease in endosomal signaling.
Due to the effective blockade of plasma membrane NK1R
calcium signaling (Fig. 2), β-arrestin recruitment, and receptor
internalization (Fig. 3) by Span-Chol, we then examined the
ability of the lipidated antagonist to affect other plasma-
membrane-dependent NK1R signaling pathways. Using an
expanded toolbox of targeted FRET biosensors, we have
mapped the signaling of the NK1R as it traffics from the plasma
membrane to endosomes. By comparing cAMP production
detected by cytosolic and plasma-membrane-localized cAMP
FRET biosensors, and delineating the temporal profiles of
cytosolic PKC activity (acute versus sustained phases), we can
show that Span-Chol is more effective at inhibiting
endosomal-selective NK1R signaling over sustained time pe-
riods. After 4 h of continuous administration, we find that
Span effectively blocks all signaling from the plasma-
membrane-localized NK1R, but has no effect on signaling
from the endosomal NK1R. In contrast, Span-Chol was unable
to block PKC or cAMP signals from the plasma membrane
NK1R but blocked all signaling from the endosomal NK1R. It is
interesting that Span-Chol appears to block NK1R Ca
2+
signaling and receptor internalization, but not cAMP or PKC
signaling from the plasma membrane. GPCRs are highly flex-
ible proteins that fluctuate between many different confor-
mational states (39, 40). They may adopt different
conformations at the plasma membrane versus in endosomes
due to large differences in the curvature of the two mem-
branes, the composition of the associated membrane lipids,
and allosteric effects of associations with receptor signaling
complexes (40–46). This could effectively facilitate slightly
different binding orientations for Span-Chol in the two loca-
tions and perhaps allow location-biased antagonism. Alterna-
tively, the enclosed and small volume of an endosome could
effectively result in a much higher local concentration of the
antagonist compared with the open and large volume of the
extracellular space. The end result is that at the plasma
membrane, Span-Chol is apparently more effective at inhibit-
ing receptor internalization and Ca2+ signaling than inhibiting
cAMP and PKC signaling. Signaling, in contrast to receptor
internalization, is typically a highly amplified event. The
recruitment of β-arrestins to a receptor, and subsequent β-
arrestin-mediated internalization, is generally considered a low
amplification event (47). In contrast, a single GPCR can acti-
vate multiple G proteins, which in turn switch on (or off) ki-
nases or enzymes. For example, it is estimated that a single
photon of light hitting a photosenstitive GPCR can activate
between 16 and 60 G proteins, which in turn activate phos-
phodiesterases to hydrolyze 2000–72,000 molecules of cGMP12 J. Biol. Chem. (2021) 296 100345(48). Small differences in the local concentration of Span-Chol
or even its binding orientation could therefore have dramatic
effects on receptor trafficking without seeming to affect
downstream signaling (such as cAMP, PKC, ERK) from the
receptor at the plasma membrane. Further studies involving,
for example, direct measurement of NK1R-G protein coupling
at the plasma membrane compared with endosomes, may
provide further insight into the mechanism of action for Span-
Chol relative to Span.
We previously showed that Span-Chol could inhibit sus-
tained pain transmission for up to 6 h following administration
in preclinical models (5). Here we extended this analysis to
show that the analgesic effects of Span-Chol are retained for
>9 h following administration. This study demonstrates that
lipidation is a viable approach, not only for enhancing mem-
brane affinity of soluble GPCR antagonists, but also for tar-
geting NK1R signaling pathways of pathophysiological
importance. Furthermore, this novel approach improves the
pharmacological properties of an otherwise less potent NK1R
antagonist and results in potent and selective inhibition of
signaling events associated with central pain transmission.
One explanation for the failure of previous drug discovery
programs targeting the NK1R for chronic pain is that they have
only targeted plasma-membrane-localized NK1R. Until very
recently, GPCRs were only considered to be active at the cell
surface, and therefore most drugs targeting GPCRs are not
required to cross the plasma membrane. There is now clear
evidence to show that activation of receptors in endosomes
(compared with the cell surface) encodes for distinct physio-
logical outcomes (5, 8, 49–52). It is therefore important to
consider the subcellular location of a target GPCR, and
whether they reside in, or are delivered to, a particular loca-
tion. For example, the β1-adrenoceptor is localized to two
distinct pools in cells: one at the cell surface and a second at
the Golgi (16). Golgi-localized signaling of the β1-adreno-
ceptor requires a preexisting pool of receptors (i.e., they are
not delivered to the Golgi following internalization from the
cell surface). In this case, as these two receptor populations are
distinct, a targeting strategy involving direct delivery would be
better suited than one that also facilitates inhibition of cell
surface receptor endocytosis. In contrast, the two NK1R re-
ceptor pools at the cell surface and endosomes are linked by
receptor internalization. As such, blockade of the endosomal
pool is further enhanced by preventing movement of the pool
at the cell surface into the endosomal network. This could
explain the prolonged analgesic activity of a lipidated-NK1R
antagonists versus an antagonist directly delivered to endo-
somes (5, 17) (Fig. 7).
Whether preventing NK1R internalization (in addition to
inhibition of endosomal NK1R signaling) would be of benefit in
situations of chronic pain is uncertain. In patients suffering
from chronic visceral pain, the NK1R is no longer available at
the cell surface, but is instead found principally within intra-
cellular compartments (35). In this case, as for the Golgi-
localized β1-adrenoceptor, there may be no added benefit of
blocking receptor internalization from the cell surface. Future
studies will need to directly compare different methods of
Lipid conjugation for targeting endosomal GPCRsendosomal drug delivery and their resulting efficacy in a va-
riety of disease models. Identifying additional mechanisms that
contribute to the increased preclinical efficacy of lipid-
anchored NK1R antagonists is an important step toward un-




The tripartite probes Span-Chol, Cy5-Chol, Cy5-OEt, and
Chol were synthesized as described previously (5, 8). Tetra-
methylrhodamine (TAMRA)-labeled SP (SP-TAMRA) was
synthesized by GL Biochem (Shanghai, China).
cDNAs
Rat NK1R-GFP, HA-NK1R, and NK1R-RLuc8 have been
described (14, 53). SNAP-NK1R was from Cisbio. CytoCKAR
(Addgene plasmid 14,870) was from A. Newton (54). CytoE-
pac2-camps was from M. Lohse (University of Wurzburg,
Germany) (9), and pmEpac2-camps was from D. Cooper
(University of Cambridge, UK) (55). KRas-Venus (56) and
Rab5a-Venus (57) were from N. Lambert. β-arrestin 2-YFP was
from M. Caron (University of North Carolina).
Cell culture and transfection
HEK293 cells (ATCC, negative for mycoplasma contami-
nation) were maintained in Dulbecco’s modified Eagle’s me-
dium (DMEM) supplemented with 5% (v/v) FBS. HEK293 cells
were transfected using linear polyethyleneimine. HEK293-
FlpIn cells stably expressing rat HA-NK1R (HEK-NK1R) and
SNAP-NK1R (HEK-SNAP-NK1R) have been described (5, 15).
HEK-NK1R and HEK-SNAP-NK1R cells were maintained in
DMEM supplemented with 10% (v/v) FBS and 100 μg/ml
Hygromycin B. All assay dishes and plates were coated with
poly-D-lysine (5 μg/cm2).
Fluorescence correlation spectroscopy (FCS)
FCS measurements were made using a Zeiss LSM510Meta
ConfoCor 3 microscope fitted with a c-Apochromat 40x NA
1.2 water immersion objective lens (58). Cy5 was excited using
a 633 nm HeNe laser, with emission collected through a 650LP
filter and the pinhole diameter of 1 Airy unit. Prior to each
experiment, Cy5 NHS ester (GE healthcare, Buckingham, UK)
was used to calibrate the 633 nm detection volume using a
literature value for diffusion coefficient (D) of 3.16 x 10-10 m2/
s, as described (22, 58).
HEK-NK1R-SNAP was plated on Nunc Lab-Tek 8-well
coverglasses (SLS, Nottingham, UK). After 24 h, Cy5-Chol
and Cy5-OEt were prepared in HBSS and cells were incu-
bated with a 10 nM solution of each ligand for 10 min at 37ºC
in a final volume of 400 μl. A reference confocal image of each
cell was captured, before positioning the FCS detection volume
in x-y using a live confocal image. A fluorescence intensity
scan in the z direction was used to determine the position of
the plasma membrane, and the focal point was positioned atdefined distances above this point using the microscope’s
harmonic z-drive. FCS fluctuations were recorded at each
point (ex λ: 633 nm HeNe, em λ: LP650 nm filter) for 20 s, at a
laser power of 1 kW/cm2.
Probe dwell times and particle numbers were obtained from
subsequent autocorrelation analysis of the fluctuations, per-
formed with a 1 component, 3D Brownian model fit incor-
porating a triplet state pre-exponential using Zeiss 2010 Black
software (22). Probe concentration and diffusion coefficients
were calculated from measurements of dwell time and particle
number, respectively, using the dimensions of the detection
volume calculated from the Cy5 calibration data.
High-content fluorescent competition binding
HEK-NK1R cells in black optically-clear 96 well plates were
grown to 80% confluency. Cells were pretreated at 37C with
increasing concentrations of Span or Span-Chol for the indi-
cated times, followed by an EC50 concentration (0.5 nM) of SP-
TAMRA. Total binding was determined by preincubation with
a vehicle control (0.1% v/v DMSO). Cell nuclei were stained
with Hoechst 33,342 (1 μg/ml, 30 min, 37C). Images were
acquired using an ImageXpress Ultra confocal high-content
plate reader (Molecular Devices, Sunnyvale, CA, USA) with
Fluor 40x NA0.6 objective and the pinhole set to 4. Cells were
imaged using the 405 nm and 561 nm laser excitations for
Hoechst (DAPI filter) and TAMRA (Texas Red filter),
respectively. The experiment was performed in triplicate with
four fields of view imaged per well. Images were analyzed with
MetaXpress 2.0 software (Molecular Devices), using an auto-
mated granularity module with the granule range set to
5–10 μm and intensity thresholds for granule classification set
for each experiment based on the positive and negative con-
trols (i.e., total and nonspecific binding). A nuclear count from
the Hoechst 33,342 image was obtained and the granularity
module calculated the average intensity per cell, as previously
described (23, 59). Data were fit with a competitive binding,
one site, fit logIC50 model.
Confocal imaging
To identify endosomal compartments, HEK293 cells were
transduced with fluorescent fusion proteins using CellLight
BacMam 2.0 virus (Life Technologies) for 16 h. CellLight
fusion proteins used were as follows: early endosome-RFP, late
endosome-GFP. Cells were equilibrated in Hanks’ Balanced
Salt Solution (HBSS) for 30 min prior to imaging.
Images were obtained using a Leica TCS SP8 Laser-
scanning confocal microscope with HCX PL APO 40x (NA
1.30) and HCX PL APO 63x (NA 1.40) oil objectives in a
humidified and temperature-controlled chamber at 37C. For
each cell, three baseline images were captured (4–6 optical
sections) before addition of Cy5-Chol (1.5 μM). Cells were
imaged at different time points following probe addition, as
indicated.
Imaging was performed on at least three different days with
separate drug preparations. Line scan intensity was processed
using the FIJI distribution of Image J (60). The proportion ofJ. Biol. Chem. (2021) 296 100345 13
Lipid conjugation for targeting endosomal GPCRsCy5 fluorescence at the plasma membrane compared with the
rest of the cell was calculated as a percentage of the raw in-
tegrated density of the total cell area.
Measurement of intracellular Ca2+
HEK-NK1R cells in 96-well plates were washed with calcium
buffer (10 mM HEPES, 0.5% w/v BSA, 10 mM D-glucose,
2.2 mM CaCl2 1.18 mM MgCl2, 2.6 mM KCl, 150 mM NaCl,
4 mM probenecid, 0.05% v/v pluronic acid F127; pH 7.4) and
then loaded with 1 μM Fura-2 AM ester (Life Technologies) in
calcium buffer for 45 min at 37C. For short preincubation
with the antagonist, increasing concentrations of Span or
Span-Chol were incubated with the cells for 30 min during
Fura-2 AM loading. For longer preincubation with the
antagonist, cells were incubated with increasing concentra-
tions of Span or Span-Chol for the indicated time periods prior
to Fura-2 AM loading.
Calcium was measured using a FlexStation 3 plate reader
(Molecular Devices). Fluorescence (excitation: 340 nm and
380 nm; emission: 520 nm) was measured at 4 s intervals for a
total of 45 s. After establishing baseline fluorescence, cells were
stimulated with vehicle, 1 nM SP, or 1 μM ionomycin (to
obtain a maximal response). SoftMax Pro (v5.4.4) software was
used to calculate the area under the curve from the kinetic data
from at least four experiments performed in duplicate.
Receptor trafficking using BRET
HEK293 cells in 10 cm dishes were cotransfected with 1 μg
of NK1R-RLuc8 and 4 μg β-arrestin 2-YFP, KRas-Venus or
Rab5a-Venus. After 24 h, cells were replated in 96-well white
opaque culture plates (CulturPlate-96; PerkinElmer). Forty-
eight h after transfection, cells were pretreated with antago-
nists. For short preincubations, cells were incubated with
increasing concentrations of Span, Span-Chol, or Chol in
HBSS for 30 min. For “pulsed” long preincubations, cells were
incubated with increasing concentrations of Span, Span-Chol,
or Chol for 30 min, washed, media was replaced for 3 h, prior
to equilibration for 30 min in HBSS (4 h total). Coelenterazine
h (Promega) was added at a final concentration of 5 μM, and
the cells were incubated for a further 5 min.
The BRET baseline was measured every 1 min for 4 min,
before addition of vehicle or 1 nM SP, with BRET measure-
ments continued every 1 min for 25 min. BRET was measured
using a PHERAstar Omega microplate reader (BMG Labtech)
with sequential integration of the signals detected at 475 ±
30 nm and 535 ± 30 nm with filters with the appropriate band
pass. Data are shown as the BRET ratio (calculated as the ratio
of the YFP/Venus signal to the RLuc8 signal) expressed as the
SP-induced change in BRET (corrected for vehicle) for time
course graphs. Curve fitting of time course data used expo-
nential equations in GraphPad Prism version 8.4.3 (plateau
followed by one-phase association for Rab5a and β-arrestin2
BRET or one-phase decay for KRas BRET). The plateau was
derived from the curve fit for each independent experiment
and is shown relative to the control SP response (BRET/
BRETSP) for bar graphs. Normal distribution of the data was14 J. Biol. Chem. (2021) 296 100345confirmed using normality (QQ) plots in GraphPad Prism
prior to statistical analysis.
Spatial PKC and cAMP using high-content and confocal
ratiometric FRET imaging
High-content ratiometric FRET imaging was performed as
described previously (61). HEK293 cells in black, optically
clear 96-well plates were grown to 70% confluency before
cotransfection with 55 ng/well HA-NK1R and 40 ng/well
cytoCKAR, pmEpac2, or cytoEpac2 for 48 h. Before the
experiment, cells were partially serum-restricted overnight in
0.5% (v/v) FBS DMEM. On the day of the experiment, cells
were preincubated with Span or Span-Chol (both 1 μM) for 4 h
before the medium was replaced with HBSS and cells were
equilibrated for 30 min at 37C. High-content fluorescence
imaging was performed using the INCell 2000 Analyzer with a
Nikon Plan Fluor ELWD 40× (NA, 0.6) objective and FRET
module (GE Healthcare) (14, 61). Cells were sequentially
excited using a CFP filter (430/24) with emission measured
using YFP (535/30) and CFP (470/24) filters with a polychroic
optimized for this filter pair (Quad 3). The FRET baseline was
measured every 1 min for 4 min, before addition of vehicle
control (0.0001% v/v MilliQ H2O) or 1 nM SP, with image
capture continued for 20 min. At the end of each experiment,
the same cells were stimulated with positive controls to
maximally activate the biosensor: 200 nM phorbol 12,13-
dibutyrate (PDBu) with phosphatase inhibitor cocktail
(Merck) for CKAR, or 10 μM forskolin with 100 μM 3-
isobutyl-1-methylxanthine for Epac2. After 10 min incuba-
tion, images were captured every 1 min for a final 4 min.
For fast confocal imaging experiments, HEK293 cells in 8-
well Ibidi chamber slides were grown to 50% confluency
before cotransfection with 110 ng/well HA-NK1R and 80 ng/
well cytoCKAR. Before the experiment, cells were partially
serum-restricted overnight in 0.5% (v/v) FBS DMEM. Forty-
eight h after transfection, cells were preincubated with Span
or Span-Chol (both 1 μM) for 4 h before the medium was
replaced with HBSS and cells were equilibrated for 30 min at
37C. Fast capture imaging was performed using a Zeiss
LSM710 confocal fluorescence microscope with a Zeiss 40x
NA1.34, oil immersion objective, with pinhole set to 2 AU.
Cells were excited at 458 nm (CFP), with dual emission
measured at 481 nm (CFP) and 540 nm (YFP). The FRET
baseline was measured every 3 s for 30 s, before addition of
vehicle control (0.0001% v/v MilliQ H2O) or 1 nM SP, with
image capture continued every 3 s for 2 min. At the end of
each experiment, the same cells were stimulated with a posi-
tive control, 200 nM PDBu, and imaged for a further 5 min.
For both high-content and fast imaging experiments, only
cells with >3% change in F/F0 (FRET ratio relative to baseline
for each cell) after stimulation with the positive controls were
selected for analysis. The average F/F0 was calculated for each
experiment and combined. Data were analyzed using in-house
scripts written for the Fiji distribution of Image J (60), as
described previously (61), with some modifications. The
updated scripts are freely available from the Monash
Lipid conjugation for targeting endosomal GPCRsUniversity online repository, Bridges (https://doi.org/10.2618
0/13289105) (62). Data were fit using a Pharmechanics “rise
and fall” time course equation (“baseline then rise-and-fall to
baseline time course with drift”), which is freely available
(https://www.pharmechanics.com/time-course-tool-pack).
Animal models of mechanical nociception
A total of 72 male C57Bl/6 mice (6–12 weeks old) were used
in this study. Mice were maintained in a temperature and
humidity-controlled room (23ºC ± 2º C) under a 12 h light/
dark cycle with food and water ad libitum. The study was
conducted in accordance with the requirements of the
Australian Code for the Care and Use of Animals for Scientific
Purposes (eighth edition, 2013) and the ethical guidelines of
the International Association for the Study of Pain (63), and
was approved by the animal ethics committee of Monash
Institute of Pharmaceutical Sciences, Monash University. Mice
were randomly assigned to experimental groups.
Mice were acclimatized to the experimental conditions on
two successive days for 1–2 h. On the day of the study,
withdrawal thresholds were measured in duplicate to establish
baseline readings for each mouse. Span, Span-Chol, Chol (all
50 μM), or vehicle (1% v/v DMSO in 0.9% w/v saline) was
injected intrathecally (5 μl, L3-L4) into the mice (n = 6 per
group) anesthetized with isoflurane inhalation (2–5% delivered
in oxygen). At 3, 6, and 12 h after drug administration,
capsaicin (5 μg, vehicle: 20% ethanol, 10% Tween 80, 70%
saline; v/v; 10 μl/mouse) was administered by intraplantar
injection under isoflurane anesthesia (2–5% delivered in oxy-
gen) to the left hindpaw. Nociception was assessed by
measuring paw withdrawal thresholds with von Frey filaments
of ascending force, applied to the plantar surface of the
hindpaws as previously described (5, 64). Paw withdrawal
thresholds were measured for both the ipsilateral and
contralateral hindpaws every hour for 4 h. The data were
subsequently normalized to the baseline paw withdrawal
threshold for each animal. Investigators were blinded to drug
treatments and experimental groups.
Data analysis
Graphs were generated using GraphPad Prism 8 (San Diego,
CA). Data are presented as mean ± S.E.M, unless otherwise
stated.
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